Governor Tim Walz's Track Record on Medical Debt, Public Option, UnitedHealth Group

By Wendell Potter - The announcement that Minnesota Governor Tim Walz will join Vice President Kamala Harris on the 2024 presidential ballot brings a noteworthy dynamic to the upcoming election. This pairing offers a blend of experience and a shared vision for the future, especially in the realm of health care — a topic that has been at the forefront of both leaders' careers. Read Full Article…

HVBA Article Summary

1. Conflict with Health Insurers: Governor Tim Walz's tenure has been marked by notable confrontations with major health insurers, particularly following the renewed ban on for-profit HMOs participating in Minnesota’s Medicaid program—a reversal of a 2017 decision. This legislative action, supported by Walz, led to significant pushback from UnitedHealthcare, resulting in a lawsuit against the state. These developments highlight the tension between Walz’s administration and health insurance conglomerates, reflecting his commitment to prioritizing public health policies over corporate profits in the healthcare sector.

2. Advocacy for Universal Health Care Access: Walz's belief in health care as a fundamental right has been a cornerstone of his political platform, expressed vividly in his inaugural address and subsequent policies. His push for a public option, aimed at expanding MinnesotaCare, indicates a strong commitment to increasing healthcare accessibility. Although the implementation of a public option has been gradual, with potential commencement in 2027, his administration has laid substantial groundwork to support this transformation.

3. Legislative Efforts on Drug Pricing and Medical Debt: Under Walz's leadership, Minnesota has taken aggressive steps towards controlling drug prices and mitigating medical debt. The expansion of the Minnesota Prescription Drug Price Transparency Act and the enactment of the Alec Smith Insulin Affordability Act are pivotal moves towards reducing healthcare costs. Furthermore, the Minnesota Debt Fairness Act, which aims to shield patients from the adverse effects of medical debt, underscores Walz’s focus on protecting consumers in the healthcare system.

Premiums for ACA plans to grow 7% next year: KFF

By Rebecca Pifer - The number of Americans in ACA coverage has swelled to record highs this year, in part due to more individuals losing Medicaid as states continue rechecking their eligibility for the safety-net coverage. Read Full Article…

HVBA Article Summary

1. Projected Premium Increases: Premiums for Affordable Care Act (ACA) exchange plans are anticipated to rise by an average of 7% in 2025, mirroring the increase seen the previous year. This hike is attributed to factors such as workforce shortages, the increasing market consolidation among hospitals, and the escalating demand for expensive GLP-1 drugs like Ozempic and Wegovy, as detailed in the KFF’s analysis of over 320 insurers’ rate filings.

2. Impact of Subsidies and Cost Drivers: While most ACA marketplace enrollees benefit from subsidies, mitigating the impact of these premium increases on their out-of-pocket costs, the overall financial burden shifts to taxpayers who fund these subsidies. The KFF highlighted that factors contributing to rising healthcare costs include higher inflation and reduced competition due to hospital consolidations, which typically lead to higher medical expenses over time.

3. Variability and Future Implications of Rate Changes: Insurers have proposed rate changes for 2025 ranging from a 14% decrease to a staggering 51% increase, with most aiming for increases between 2% and 10%. This variability indicates differing regional healthcare cost dynamics and insurer strategies. The scheduled expiration of enhanced federal subsidies by the end of next year poses additional challenges, potentially leading to significant increases in the number of uninsured individuals, according to estimates from the Congressional Budget Office.

Appeals court upholds ruling that struck down surprise billing arbitration process

By Paige Minemyer - A federal appeals court has upheld a lower court decision that struck down key parts of legislation aimed at reforming surprise medical billing. The Fifth Circuit Court's ruling, which was filed late last week, confirms a February 2023 decision from the court in the Eastern District of Texas, vacating arbitration methodology set by the Centers for Medicare & Medicaid Services (CMS). Read Full Article…

HVBA Article Summary

1. Legal Challenge and Initial Ruling: The Texas Medical Association (TMA) filed a lawsuit against the Department of Health and Human Services, challenging the arbitration methodology under the No Surprises Act (NSA), which they argued unfairly favored insurers by prioritizing the qualified payment amount (QPA) in dispute resolutions. This led to a judicial decision where the Fifth Circuit judges agreed, stating that this interpretation was inconsistent with the act's intention of fairness.

2. Biden Administration's Appeal: Following the adverse ruling that the Centers for Medicare & Medicaid Services' (CMS) dispute resolution framework was biased, the Biden administration decided to appeal the decision. This appeal reflects ongoing contention about how best to implement the NSA's provisions without disproportionately favoring either healthcare providers or payers.

3. Future of Arbitration and CMS Actions: While the future course of arbitration under the NSA remains uncertain, CMS has temporarily halted arbitration processes pending further legal clarifications. This pause indicates a cautious approach by CMS as they reconsider their methodology in light of the judicial ruling, striving to align more closely with the legislation's requirements and goals. Meanwhile, the TMA has expressed hope that this ruling definitively resolves the issue, emphasizing the need for a fair mechanism to protect patients from surprise medical bills.

New law aims to speed up insurance pre-approvals in New Hampshire

By Paul Cuno-Booth - Medical treatments often need to be pre-approved by insurance – what’s known as “prior authorization.” But many doctors and patients complain the process can be burdensome, causes delays and sometimes prevents people from getting necessary care. Read Full Article…

HVBA Article Summary

1. Timely Response Mandates: The new state law in New Hampshire establishes strict deadlines for insurers to process prior authorization requests. For urgent medical situations, insurers are required to provide a response within 72 hours or sooner depending on the patient's condition. For non-urgent procedures, the response time is set at seven days, provided that the requests are submitted electronically. Failure to meet these deadlines results in automatic approval of the procedures.

2. Expertise in Authorization Decisions: Under the new legislation, insurers are mandated to involve qualified medical experts to assess the medical necessity of procedures. This aims to ensure that decisions on prior authorizations are evidence-based and appropriate, addressing concerns that decisions were previously made by individuals possibly not specialized in the relevant medical fields.

3. Stakeholder Involvement and Bipartisan Support: The law was shaped with contributions from various stakeholders, including the health insurance industry, which testified in support of the final version of the bill. The legislation, sponsored by Republican state Senator Denise Ricciardi and signed by Governor Chris Sununu, received bipartisan support, highlighting a unified approach to improving the efficiency and effectiveness of the prior authorization process in healthcare.

Only half of Gen Z understands basic insurance terms, study finds

By Alan Goforth - Although more than one-third of Gen Z adults pay for a cellphone protection plan, only 21% have a renters insurance policy. This discrepancy points to a need for better education about risk and why having the right insurance coverage matters. Read Full Article…

HVBA Article Summary

1. Widespread Anxiety and Delay in Insurance Adoption: The survey highlights that a significant portion of Gen Z adults feels overwhelmed or anxious about dealing with insurance matters, with over half of the respondents expressing such feelings. Moreover, about one-third of young adults are procrastinating on obtaining life insurance, and a similar proportion is hesitant about getting health insurance coverage.

2. Lack of Knowledge on Key Insurance Concepts: There is a notable gap in understanding essential insurance terms among Gen Z adults. Only 27% can define "deductible" and 29% "copay," while a slightly higher percentage understand the term "out of pocket." Awareness of the importance of various types of insurance, such as auto and health, is also insufficient among many Gen Z respondents.

3. Potential for Improvement Through Education and Resources: Despite these challenges, there is a foundation for optimism as a majority of surveyed Gen Z adults are independently managing their health insurance, and nearly half have their automobile coverage. State insurance departments play a crucial role in offering objective information and support, helping to bridge these knowledge gaps and ensuring that consumers understand and can navigate the insurance landscape effectively.

HealthCare.gov hopes to profit from ICHRA boom

By Allison Bell - This could be the year when the Centers for Medicare and Medicaid Services finally turns HealthCare.gov into a serious health benefits player. Read Full Article…

HVBA Article Summary

1. Rapid Increase in Registrations: HealthCare.gov saw a significant increase in agent and broker registrations within the first four days of opening this year, with 831 registrations compared to just 231 during the same period in 2023. This uptick reflects a growing interest and engagement among producers in utilizing the platform's services.

2. New Reimbursement Options Highlighted: HealthCare.gov is actively promoting new reimbursement programs such as the Qualified Small Employer Health Reimbursement Arrangement (QSEHRA) and the Individual Coverage Health Reimbursement Arrangement (ICHRA). These programs enable employers to provide funds directly to employees to purchase their own guarantee-issue, community-rated health coverage through the platform, offering an alternative to traditional group plans.

3. Supportive Resources and Guides: To assist employers and producers in understanding and comparing the new health coverage options, HealthCare.gov has published a comprehensive guide detailing QSEHRA, ICHRA, and SHOP plans. Additionally, companies like HealthSherpa are capitalizing on this shift by offering tailored guides and marketing services to facilitate the adoption of these new reimbursement models by employers and brokers.

Medicare doctor pay, PBM bills in limbo as Congress takes off

By Michael McAuliff - Members of Congress headed home for the summer over the weekend, leaving the healthcare community in an all-too-familiar position: Wondering how key priorities will turn out after lawmakers failed to address them in the first part off the year. Read Full Article…

HVBA Article Summary

1. Funding Cuts and Program Expirations: Beginning in January, there are significant financial concerns for the healthcare sector, including an $8 billion reduction in Medicaid disproportionate share hospital payments, a 2.9% cut in Medicare physician reimbursements, and the expiring funding for crucial community health centers. These impending changes pose a risk to the stability of healthcare services, particularly for underserved communities.

2. Legislative Stalemate on Healthcare Reform: Congress has been attempting to advance major healthcare reforms, including regulating pharmacy benefit managers, mandating transparency, enacting site-neutral payments, and extending telehealth services. However, with Congress not set to reconvene until September and only a few weeks left before the fiscal year ends, the passage of these reforms is uncertain. The political dynamics, intensified by election campaigns and partisan disagreements, further complicate the legislative process.

3. Continuing Resolutions and Election Impacts: The likelihood of Congress passing a continuing resolution to keep government functions running is high, yet even this stopgap measure is fraught with complexities due to the approaching elections and recent shifts in political leadership dynamics. With limited legislative days available and a packed agenda that includes the National Defense Authorization Act, there is growing skepticism about substantial progress on healthcare legislation before the election.

Drug cost inflation to rise 3.8% in 2025, report shows

By Maia Anderson - Inflation has hit the pharmacy shelves. The drug price inflation rate is expected to hit 3.8% next year, thanks largely to increased use of expensive medications like GLP-1s and cell and gene therapies, according to new data from healthcare services firm Vizient’s summer Pharmacy Market Outlook report. Read Full Article…

HVBA Article Summary

1. Rising Costs of GLP-1 Drugs: Spending on Novo Nordisk’s semaglutide, marketed as Wegovy, has surged by 77% in 2024 compared to the previous summer, as reported by Vizient. The increasing expenditure on GLP-1 drugs, which are being explored for a widening array of treatable diseases, is becoming a significant financial consideration for healthcare providers managing pharmacy budgets.

2. High Price of Cell and Gene Therapies: Vizient highlights the substantial financial impact of cell and gene therapies, which can cost between $250,000 and $4.3 million per dose. These therapies, targeting conditions like sickle cell anemia and spinal muscular atrophy, are expected to grow in popularity and strain budgets as nearly 300 such treatments are currently undergoing clinical trials.

3. Challenges with CAR-T Therapies: The costs associated with chimeric antigen receptor T-cell (CAR-T) therapies, specifically approved for treating blood cancers, are also escalating, with each treatment exceeding $455,000. Carina Dolan of Vizient emphasized the need for health systems to develop multidisciplinary strategies to manage these high-cost treatments effectively, involving early patient identification, securing access to therapies, and coordinating the complex logistics of drug administration.

Too Much Coffee Linked to Accelerated Cognitive Decline

By Pauline Anderson - Drinking more than three cups of coffee a day is linked to more rapid cognitive decline over time, results from a large study suggest. Investigators examined the impact of different amounts of coffee and tea on fluid intelligence — a measure of cognitive functions including abstract reasoning, pattern recognition, and logical thinking. Read Full Article…

HVBA Article Summary

1. Global Beverage, Local Impact: Coffee, consumed globally, contains numerous bioactive compounds like caffeine and chlorogenic acid. Consistently, research links moderate coffee and tea intake to various health benefits, such as reduced risks of stroke, heart failure, and certain types of cancer. Recent findings presented at the Alzheimer's Association International Conference 2024 also suggest potential protective effects against cognitive decline and Alzheimer's disease.

2. Study Insights and Patterns: The recent study, examining over 8,000 cognitively unimpaired older adults, categorized their coffee and tea consumption into high, moderate, and none. Results from linear mixed models revealed that moderate coffee drinkers had a slower decline in fluid intelligence compared to those who consumed high amounts or none at all. In contrast, never drinking tea was associated with greater cognitive decline than moderate or high tea consumption.

3. Potential Mechanisms and Future Research: Despite the observational nature of the study, which calls for further confirmation through randomized controlled trials, preliminary data suggest that moderate coffee consumption might offer some protection against cognitive decline, potentially through molecular mechanisms involving amyloid toxicity or behavioral patterns like sleep. This opens new research avenues for developing preventive strategies against Alzheimer's disease.